Clinical trial
Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel…
NCT00424606 · Hellenic Oncology Research Group, Other · Completed
Key facts
| NCT number | NCT00424606 |
|---|---|
| Title | Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients |
| Official title | A Multicenter Randomized Phase III Study of Adjuvant Treatment With Epirubicin Followed by Docetaxel (E/T) Versus Epirubicin and Docetaxel Combination (ET) in High Risk Lymph Node Negative Breast Cancer Patients |
| Lead sponsor | Hellenic Oncology Research Group, Other |
| Collaborators | University Hospital of Crete |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Epirubicin |
| Enrollment | 658 |
| Start date | Jun 1, 2001 |
| Primary completion | Aug 1, 2013 |
| Completion | Aug 1, 2013 |
| First posted | Jan 19, 2007 |
| Last update posted | May 20, 2015 |
| Countries | Greece |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: